Brief: Gracell Biotechnologies' Abstract on CAR-T Cell Therapy Accepted for Presentation at 2022 ASCO Annual Meeting
14/04/2022 13:42
April 14 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES' ABSTRACT ON GC012F, A BCMA/CD19
DUAL-TARGETING CAR-T CELL THERAPY, ACCEPTED FOR PRESENTATION AT
2022 ASCO ANNUAL MEETING
Source text for Eikon: ID:nPn9hlF0pa
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27